These trials are based on 227Th-labeled anti-PSMA-HOPO (Bay 2315497) and 227Th-labeled anti-mesothelin-HOPO for the treatment of PCa (NCT03724747) [355] and mesothelioma (Bay 2287411), respectively. This evidence concerns the gene FOLH1 and posterior cortical atrophy.